Telix Pharmaceuticals Limited

Courtney Watson knows the pain of uncertainty that can come with brain tumor imaging — waiting for scan results, monitoring for progression, and searching for clarity in a disease where every day matters. After losing her mother to glioblastoma less than nine months after diagnosis, Courtney dedicated herself to supporting other patients and families facing the battle with brain cancer. Today, as Director of Programs and Communications at Head for the Cure Foundation, she helps connect the brain tumor community with support programs, advocacy initiatives and research funding opportunities. During Brain Tumor Awareness Month, Telix is sharing stories from patients, caregivers and advocates working to improve the lives of those affected by brain cancer. To learn more about Head for the Cure, including upcoming 5K runs and walks and patient support resources, visit: headforthecure.org U.S. healthcare professionals can explore diagnostic challenges in glioma at: gliomagrayareas.com For more on Telix’s brain cancer portfolio, visit: telixpharma.com/brain

Telix has completed enrolment in the IPAX-2 Phase 1 study evaluating the safety and tolerability of TLX101-Tx (¹³¹I-iodofalan) in combination with post-surgical standard-of-care treatment in patients with newly diagnosed glioblastoma. The maximum administered dose was reached with no dose-limiting toxicities observed to date. This milestone marks an important step forward in the continued development of Telix’s LAT1-targeted therapeutic candidate for one of the most aggressive and difficult-to-treat cancers. TLX101-Tx is also being evaluated in the pivotal IPAX BrIGHT trial, which is actively enrolling and dosing patients with recurrent glioblastoma in combination with lomustine chemotherapy. Read more: https://lnkd.in/gGhKSQW3 NCT05450744 TLX101-Tx has not received a marketing authorization in any jurisdiction.

Telix has announced collaboration initiatives with EDAP TMS (Focal One) and Profound Medical Inc., leading developers of minimally invasive and image-guided ablative technologies for prostate cancer. The collaborations will explore the investigational use of Telix’s PSMA-PET imaging agents, Gozellix® (kit for the preparation of 68Ga-PSMA-11 injection) and Illuccix® (kit for the preparation of 68Ga-PSMA-11 injection), across emerging treatment workflows for localized prostate cancer, including robotic high-intensity focused ultrasound (HIFU) and transurethral ultrasound ablation (TULSA). Activities will focus on patient selection, treatment planning and post-treatment monitoring, with evidence generated expected to help inform best practice and support the integration of molecular imaging into evolving prostate cancer treatment paradigms. Read more: https://lnkd.in/gPdDxBMh PSMA-PET imaging is not currently approved for specific treatment-planning indications associated with these emerging therapies.

Telix is in Canberra this week for the ANZSNM Annual Scientific Meeting 2026. We're proud to support the premier event for nuclear medicine in Australia and New Zealand, with Telix's diagnostic and therapeutic programs featured across six oral presentations spanning prostate, kidney, and brain cancer. Come meet the team at booth #29 to learn more about Telix's extensive late-stage theranostic pipeline, along with our associated medical technologies, AI tools, and opportunities for collaboration. Telix is also pleased to again support the ANZSNM Nurses' Workshop, bringing together nuclear medicine nurses and allied health professionals from across Australia and New Zealand to share clinical experience and advance best practice in theranostic care. Swipe to view all presentations, and follow the link to learn more about Telix at ANZSNM ASM: https://lnkd.in/g3U-S6ZZ

Join Telix at the American Urological Association’s 2026 Annual Meeting, taking place this week in Washington, DC. #AUA2026 will feature presentations across Telix’s urologic oncology portfolio, including ⁸⁹Zr-girentuximab PET/CT (TLX250-Px) for kidney cancer imaging and ⁶⁸Ga-PSMA-11 PET combined with MRI for the detection of prostate cancer (Phase 3 BiPASS trial). The presentations highlight the increasing role of targeted imaging in supporting diagnosis, treatment planning and disease management across these disease areas with unmet need. Join us at these presentations or visit us at Booth #1215 to chat to #TeamTelix. Swipe to view the presentation details and follow the link to learn more: https://lnkd.in/g2NdWzFs TLX250-Px has not received a marketing authorization in any jurisdiction.

This May, Telix is proud to support Brain Tumor Awareness Month and help raise awareness of the unmet need in brain cancer. Glioblastoma is one of the most aggressive and difficult-to-treat primary brain tumors, with limited effective treatment options and no standard of care currently established for recurrent disease. At Telix, we are developing investigational diagnostic and therapeutic candidates in neuro-oncology, with the aim of supporting more precise detection and targeted treatment approaches for patients living with brain cancer. U.S. healthcare professionals can learn more about the challenges in brain imaging at: gliomagrayareas.com To learn more about Telix’s neuro-oncology portfolio, visit telixpharma.com/brain

Telix today announces the publication of a new independent analysis of Phase 3 ZIRCON trial data in European Urology, demonstrating that TLX250-Px (Zircaix®) PET/CT imaging may be highly predictive of renal malignancy across all subtypes, not limited to clear cell renal cell carcinoma (ccRCC). These exploratory scientific findings support continued evaluation of TLX250-Px PET imaging across a broader spectrum of renal malignancies and highlight its potential role in the management of patients with non-ccRCC. Furthermore, almost all false-positives for ccRCC in the ZIRCON study have now been shown to be other malignant kidney cancer subtypes, reducing the risk of overtreatment and further supporting clinical adoption. Explore the key findings in the carousel below and read the full publication here: https://lnkd.in/gRep8pbf These published findings are based on exploratory analyses and are not the basis of Telix’s BLA submission for TLX250-Px, which focuses exclusively on detection of ccRCC in primary renal masses. TLX250-Px has not received a marketing authorization in any jurisdiction. Brand name subject to final regulatory approval.

This May, Telix is proudly going gray to support Brain Tumor Awareness Month. Despite decades of research, treatment advances for glioblastoma – the most common and aggressive primary brain tumor – have been limited, and no standard of care exists for recurrent disease. This month aims to raise awareness of the challenges faced by people living with brain tumors and the urgent need for continued research and innovation. At Telix, we are dedicated to developing diagnostic and therapeutic solutions to help improve outcomes for patients affected by brain cancer. U.S. healthcare professionals can learn more about the challenges in brain imaging at: https://lnkd.in/eada-UVb To learn more about Telix’s neuro-oncology portfolio, visit telixpharma.com/brain #BTAM Brain Tumour Alliance Australia (BTAA) Cure Brain Cancer Foundation Mark Hughes Foundation Centre for Brain Cancer Research Mark Hughes Foundation Beanie for Brain Cancer Peace of Mind Foundation Australia American Brain Tumor Association International Brain Tumour Alliance National Brain Tumor Society

Telix announces that its European Marketing Authorization Application for TLX101-Px (¹⁸F-FET), an investigational PET imaging agent for glioma, has been validated and accepted for review. In Europe, there is currently no generally available commercial ¹⁸F-FET PET imaging product. If approved, TLX101-Px has the potential to expand patient access to this advanced modality, supporting more timely and accurate clinical decision-making for adults and children with progressive or recurrent glioma. Read more on our website here: https://lnkd.in/gs2jzhkg

Missed the live session? Telix’s educational webinar exploring the evolution of PSMA-targeted radionuclide therapy and our multi-product approach to prostate cancer treatment is now available on demand. Professor Louise Emmett discusses what makes an effective PSMA-targeted therapy and shares data from her OPTIMAL-PSMA investigator-initiated trial of TLX597-Tx, Telix’s novel small molecule candidate. Dr. David N. Cade explains how TLX597-Tx is being developed alongside TLX591-Tx, our lead radio antibody-drug conjugate candidate in prostate cancer as part of a therapeutic portfolio designed to address distinct disease stages and patient conditions. Watch the webinar here: https://lnkd.in/gGjk3Jjk TLX591-Tx and TLX597-Tx have not received marketing authorizations in any jurisdiction.